NCT05263947View on ClinicalTrials.gov

Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 30, 2022

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2023

Conditions
Carcinoma, Non-Small-Cell LungBevacizumabEGF-R Positive Non-Small Cell Lung CancerTyrosine Kinase Inhibitor
Interventions
DRUG

Bevacizumab and Icotinib

Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle; Icotinib orally twice daily at 250mg/day

Trial Locations (1)

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER